TBC1D3B

Across TCGA pan-cancer cohorts, TBC1D3B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TBC1D3B data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TBC1D3B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TBC1D3B expression acts as an unfavorable survival marker.

HNSC and LUAD are the cancer types where TBC1D3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.087	0.710	<.001	36	view →
LUAD	OS	Median	All	0.309	0.685	.020	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TBC1D3B–HNSC (DFS)

Open the HNSC breakdown →